Advertisement

Topics

Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily

2014-08-27 03:12:48 | BioPortfolio

Summary

To evaluate the efficacy, dose response and safety of four doses of GSK2190915 in tablet form (10mg, 30mg, 100mg and 300mg) administered once daily, over 8 weeks compared with placebo in adolescent and adult subjects (12 years of age and older) with persistent asthma. These data will form the basis for the selection of the optimal daily dose of GSK2190915 to be carried forward in Phase III asthma studies. The study also includes Fluticasone Propionate Inhalation Powder (100 mcg, twice daily) and Montelukast (10mg, once daily) to allow for an exploratory analysis of the efficacy of GSK2190915 versus a low dose inhaled coticosteroid and a leukotriene receptor antagonist.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Conditions

Asthma

Intervention

GSK2190915 30mg, GSK2190915 300mg, GSK2190915 100mg, GSK2190915 10mg, Montelukast 10mg, Placebo, Fluticasone Propionate 100mcg BD

Location

GSK Investigational Site
San Diego
California
United States
92123

Status

Recruiting

Source

GlaxoSmithKline

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:12:48-0400

Clinical Trials [385 Associated Clinical Trials listed on BioPortfolio]

Study in Mild Asthmatic Patients

The purpose of this study is to determine the safety and usefulness of GSK2190915 in asthmatic patients who develop asthma symptoms following being challenged.

GSK2190915 Moderate to Severe Asthma Study

A randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect of treatment with GSK2190915, a FLAP inhibitor, as add-on to current inhaled corticosteroid ther...

A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise

This study is intended to determine the dose response and duration of action of GSK2190915 in mild asthmatic adult subjects who experience exercise-induced bronchoconstriction.

RESIST-2: 2nd-line ART for HIV-2 Infection

Prospective, longitudinal, open label, HIV-2 viral load and antiretroviral resistance informed 2nd-line ARV implementation study.

Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg

Healthy male volunteers were administered alone and in combination with dapoxetine 30mg mirodenafil 100mg for three times, respectively and the pharmacokinetic interaction was compared bet...

PubMed Articles [61 Associated PubMed Articles listed on BioPortfolio]

A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminemia receiving continuous venovenous hemodiafiltration.

We present a pharmacokinetic case-study of intravenous posaconazole in a 49-years-old male patient with intra-abdominal sepsis and hypoalbuminemia receiving continuous venovenous hemodiafiltration. Co...

Response to different benznidazole doses in animal models of chronic phase Chagas disease: a critical review.

Chagas disease is a protozoan infection that was identified over a century ago. No drugs are available to treat the indeterminate and determinate chronic phases of the disease. Success of a drug desig...

Paeoniflorin regulates GALNT2-ANGPTL3-LPL pathway to attenuate dyslipidemia in mice.

N-acetylgalactosaminyltransferase 2-Angiopoietin-like protein 3-lipoprotein lipase (GALNT2-ANGPTL3-LPL) pathway may be a useful pharmacologic objective for dyslipidemia. The present study was conducte...

Effects of CeO2 nanoparticles on the HO-1, NQO1 and GCLC expression in the testes of diabetic rats.

CeO2 nanoparticles (CNPs) as effective ROS scavengers exhibit potent antioxidant activity. In this study the effect of CNPs investigated was on HO-1, NQO1 and GCLC expression in the streptozotocin (ST...

Oxymatrine prevents the development of monocrotaline-induced pulmonary hypertension via regulation of the N, N-dimethyl-L-arginine metabolism pathways in rats.

The purpose of this study was to investigate the potential effect of oxymatrine in monocrotaline-induced pulmonary hypertension and its possible influence on the N,N-dimethyl-L-arginine (ADMA) metabol...

Medical and Biotech [MESH] Definitions

None available.

More From BioPortfolio on "Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Asthma
Asthma is caused by inflammation of small tubes, called bronchi, which carry air in and out of the lungs. If you have asthma, the bronchi will be inflamed and more sensitive than normal.  When you come into contact with something that irritates your...


Searches Linking to this Trial